A detailed history of Virtus ETF Advisers LLC transactions in Uni Qure N.V. stock. As of the latest transaction made, Virtus ETF Advisers LLC holds 17,556 shares of QURE stock, worth $277,911. This represents 0.04% of its overall portfolio holdings.

Number of Shares
17,556
Previous 17,243 1.82%
Holding current value
$277,911
Previous $77,000 11.69%
% of portfolio
0.04%
Previous 0.04%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.78 - $10.12 $1,183 - $3,167
313 Added 1.82%
17,556 $86,000
Q2 2024

Aug 14, 2024

BUY
$4.39 - $5.43 $28,754 - $35,566
6,550 Added 61.26%
17,243 $77,000
Q1 2024

May 15, 2024

SELL
$4.82 - $6.93 $3,552 - $5,107
-737 Reduced 6.45%
10,693 $55,000
Q4 2023

Feb 15, 2024

BUY
$5.63 - $8.27 $35,615 - $52,316
6,326 Added 123.94%
11,430 $77,000
Q3 2023

Nov 07, 2023

SELL
$6.71 - $11.83 $3,401 - $5,997
-507 Reduced 9.04%
5,104 $34,000
Q2 2023

Aug 14, 2023

BUY
$11.12 - $22.2 $14,511 - $28,971
1,305 Added 30.31%
5,611 $64,000
Q1 2023

May 15, 2023

SELL
$18.7 - $23.07 $30,836 - $38,042
-1,649 Reduced 27.69%
4,306 $86,000
Q4 2022

Feb 14, 2023

SELL
$18.12 - $27.32 $33,467 - $50,460
-1,847 Reduced 23.67%
5,955 $134,000
Q3 2022

Nov 14, 2022

BUY
$16.98 - $25.54 $882 - $1,328
52 Added 0.67%
7,802 $146,000
Q2 2022

Aug 12, 2022

BUY
$13.15 - $20.45 $29,416 - $45,746
2,237 Added 40.58%
7,750 $144,000
Q1 2022

May 16, 2022

SELL
$14.54 - $21.5 $4,769 - $7,052
-328 Reduced 5.62%
5,513 $100,000
Q4 2021

Feb 14, 2022

SELL
$20.24 - $36.01 $4,979 - $8,858
-246 Reduced 4.04%
5,841 $121,000
Q3 2021

Nov 15, 2021

SELL
$26.01 - $38.22 $8,427 - $12,383
-324 Reduced 5.05%
6,087 $195,000
Q2 2021

Aug 10, 2021

SELL
$29.97 - $37.17 $1,678 - $2,081
-56 Reduced 0.87%
6,411 $197,000
Q1 2021

May 17, 2021

BUY
$29.24 - $42.03 $3,304 - $4,749
113 Added 1.78%
6,467 $218,000
Q4 2020

Feb 12, 2021

BUY
$35.35 - $50.67 $51,646 - $74,028
1,461 Added 29.86%
6,354 $230,000
Q3 2020

Nov 13, 2020

SELL
$35.98 - $47.66 $23,530 - $31,169
-654 Reduced 11.79%
4,893 $180,000
Q2 2020

Aug 05, 2020

BUY
$45.06 - $67.74 $31,181 - $46,876
692 Added 14.25%
5,547 $250,000
Q1 2020

May 14, 2020

SELL
$40.01 - $73.97 $28,247 - $52,222
-706 Reduced 12.7%
4,855 $230,000
Q4 2019

Feb 13, 2020

BUY
$37.13 - $74.62 $77,416 - $155,582
2,085 Added 59.98%
5,561 $399,000
Q3 2019

Nov 12, 2019

SELL
$39.36 - $76.8 $7,635 - $14,899
-194 Reduced 5.29%
3,476 $137,000
Q2 2019

Aug 13, 2019

SELL
$52.76 - $82.19 $309,859 - $482,701
-5,873 Reduced 61.54%
3,670 $287,000
Q1 2019

May 14, 2019

SELL
$27.39 - $68.41 $31,087 - $77,645
-1,135 Reduced 10.63%
9,543 $569,000
Q4 2018

Feb 05, 2019

SELL
$22.8 - $33.93 $63,224 - $94,087
-2,773 Reduced 20.62%
10,678 $308,000
Q3 2018

Nov 14, 2018

SELL
$29.75 - $43.08 $285,957 - $414,084
-9,612 Reduced 41.68%
13,451 $489,000
Q2 2018

Aug 10, 2018

SELL
$21.96 - $39.94 $426,924 - $776,473
-19,441 Reduced 45.74%
23,063 $872,000
Q1 2018

May 14, 2018

BUY
$17.1 - $26.61 $387,520 - $603,035
22,662 Added 114.21%
42,504 $999,000
Q4 2017

Feb 14, 2018

BUY
$9.47 - $19.59 $187,903 - $388,704
19,842
19,842 $389,000

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $740M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Virtus ETF Advisers LLC Portfolio

Follow Virtus ETF Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.